Cantor Fitzgerald Reiterates Overweight on AVITA Medical, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on AVITA Medical (NASDAQ:RCEL) and maintained a $21 price target.
August 09, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on AVITA Medical and maintained a $21 price target.
The reiteration of an Overweight rating and a maintained price target of $21 by a reputable analyst is likely to positively impact AVITA Medical's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100